



UPDATE ON THE IMPACT OF THE COVID-19 PANDEMIC ON THE GROUP'S OPERATIONS

The Board of Directors (the “**Board**”) of TalkMed Group Limited (the “**Company**”) wishes to update the shareholders of the Company with regards to the impact of the COVID-19 pandemic on the Company, its subsidiaries and associated company (collectively, the “**Group**”).

While the global spread of the COVID-19 appears to have slowed with some countries easing certain restrictions that were previously put in place, many countries and regions, including Singapore and Hong Kong, continue to maintain travel restrictions, which have negatively impacted the normally resilient healthcare sector in which the Group operates.

Singapore operations

The government has announced that all short-term visitors (from anywhere in the world) would not be allowed to enter or transit through Singapore with effect from 23 March 2020.

As a large number of our patients come from the Southeast Asia region, the current travel restrictions prevent our centres in Singapore from taking in new overseas patients and deter most of our existing overseas patients from coming to Singapore for their follow-up appointments and/ or treatments, which have adversely affected the number of overseas patients seeking treatments at our centres in Singapore.

In addition, following the elevated set of safe distancing measures as a circuit breaker to pre-empt the trend of increasing local transmission of COVID-19 that were in place since 7 April 2020, certain healthcare services, such as screening services which are essential to the diagnoses of cancer, have been deemed non-essential. As a result, the number of local patients seeking treatments at our centres in Singapore have also been adversely affected.

Hong Kong operations

The government of the Hong Kong Special Administrative Region prohibits all non-Hong Kong residents from overseas countries and regions from entering Hong Kong by air while compulsory quarantine at designated places (home or other accommodation) is imposed on inbound travellers (both Hong Kong and non-Hong Kong residents) from Mainland China, Macao or Taiwan. Such measures have similarly affected the patient numbers of our Hong Kong centres, in particular, those from Mainland China.

Considering all the above developments and uncertainties, the Board expects the Group's financial performance during the first half year ending 30 June 2020 (“**1H FY20**”) to be adversely affected as compared to the corresponding period. The full extent of the COVID-19 impact on the Group's financial performance for the financial year ending 31 December 2020 and beyond cannot be ascertained at this point.



Amidst the current restrictions, we remain committed to providing quality services to our patients, which include, among others, sending oral cancer medicine to our patients who are physically overseas, remotely providing advice by our local medical team as well as our regional support by our regional representative offices.

The Company will continue to monitor the COVID-19 situation closely and the Board will provide further updates as and when any material developments arise.

By Order of the Board

Ang Peng Tiam
Chief Executive Officer
14 May 2020

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581. Telephone number: (65) 6415 9886